Homocysteine Assay Kit (Fluorometric) (ab228559) allows for quantification of total homocysteine in biological fluids such as plasma and serum. The assay is based on the reduction of homocysteine disulfides to free homocysteine, which is cleaved by a homocysteine-selective enzyme, generating an intermediate product. The intermediate reacts with a probe solution to form a stable fluorophore that emits in the far-red spectrum (Ex/Em = 658/708 nm). The assay is not affected by physiological concentrations of other biological thiols (such as cysteine, methionine and glutathione), is high-throughput adaptable and can detect as low as 5 μM homocysteine.
This product is manufactured by BioVision, an Abcam company and was previously called K531 Homocysteine Assay Kit (Fluorometric). K531-100 is the same size as the 100 test size of ab228559.
Homocysteine is a non-proteogenic amino acid synthesized intracellularly by removal of the N-methyl group from the essential amino acid methionine. Homocysteine is exported from cells into the blood, where it exists mainly as an oxidized disulfide species, either as a dimer or bound to cysteine residues of serum proteins. The reduced form of homocysteine ('free' homocysteine) can be metabolized into cysteine via the transsulfuration pathway; however, it can also undergo intramolecular cyclization, forming the highly reactive pro-oxidant homocysteine thiolactone. Subsequent N-homocysteinylation of protein lysine residues by the reactive thiolactone disrupts protein conformation, leading to formation of cytotoxic protein aggregates. Homocysteinylated proteins may also act as autoantigens, triggering arterial inflammation and atherosclerosis. Elevated plasma homocysteine concentration is a clinical biomarker for increased risk of cardiovascular disease, ischemic stroke and myocardial infarction. Severely elevated homocysteine levels (hyperhomocysteinemia) are correlated with a 4-fold increase in mortality due to heart attack and a 16-fold increase in the likelihood of recurrent stroke.
The Safety Datasheet for this product has been updated for certain countries. Please check the current version in the Support and downloads section.
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
